{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:29:35Z","timestamp":1791836975021,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"PharmaMar, S.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No systemic treatment has been established for meningioma progressing after local therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, multicenter, open-label, phase II study included adult patients with recurrent WHO grade 2 or 3 meningioma. Patients were 2:1 randomly assigned to intravenous trabectedin (1.5 mg\/m2 every 3 weeks) or local standard of care (LOC). The primary endpoint was progression-free survival (PFS). Secondary endpoints comprised overall survival (OS), objective radiological response, safety, quality of life (QoL) assessment using the QLQ-C30 and QLQ-BN20 questionnaires, and we performed tissue-based exploratory molecular analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety patients were randomized (n = 29 in LOC, n = 61 in trabectedin arm). With 71 events, median PFS was 4.17 months in the LOC and 2.43 months in the trabectedin arm (hazard ratio [HR] = 1.42; 80% CI, 1.00-2.03; P = .294) with a PFS-6 rate of 29.1% (95% CI, 11.9%-48.8%) and 21.1% (95% CI, 11.3%-32.9%), respectively. Median OS was 10.61 months in the LOC and 11.37 months in the trabectedin arm (HR = 0.98; 95% CI, 0.54-1.76; P = .94). Grade \u22653 adverse events occurred in 44.4% of patients in the LOC and 59% of patients in the trabectedin arm. Enrolled patients had impeded global QoL and overall functionality and high fatigue before initiation of systemic therapy. DNA methylation class, performance status, presence of a relevant co-morbidity, steroid use, and right hemisphere involvement at baseline were independently associated with OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Trabectedin did not improve PFS and OS and was associated with higher toxicity than LOC treatment in patients with non-benign meningioma. Tumor DNA methylation class is an independent prognostic factor for OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noab243","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T23:24:56Z","timestamp":1634167496000},"page":"755-767","source":"Crossref","is-referenced-by-count":64,"title":["Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"first","affiliation":[{"name":"Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Silvani","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"University of Lille, U-1192, Lille, France"},{"name":"Inserm, U-1192, Lille, France"},{"name":"General and Stereotaxic Neurosurgery Service, CHU Lille, Lille, France"},{"name":"Medical Oncology Department, Oscar Lambret Center, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Soffietti","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-2132","authenticated-orcid":false,"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Department of Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Sepulveda","sequence":"additional","affiliation":[{"name":"Neurooncology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Brazil","sequence":"additional","affiliation":[{"name":"St Thomas\u2019 Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bonneville-Levard","sequence":"additional","affiliation":[{"name":"Centre Leon Berard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Lorgis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Georges Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Vauleon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Eugene Marquis, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacoline","family":"Bromberg","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, Erasmus MC University Medical Center Cancer Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Erridge","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Cameron","sequence":"additional","affiliation":[{"name":"Bristol Cancer Institute, University Hospitals Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lefranc","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Oncology, KU Leuven, Leuven, Belgium"},{"name":"Department of General Medical Oncology, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dumont","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Gustave-Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sanson","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle \u00e9pini\u00e8re, ICM, AP-HP, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix, Service de Neurologie 2-Mazarin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Bronnimann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bordeaux University Hospital-CHU, Bordeaux, France"},{"name":"University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Balan\u00e1","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Thon","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine and University Hospital, University of Munich (LMU), Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lewis","sequence":"additional","affiliation":[{"name":"Freeman Hospital, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J","family":"Mair","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Sievers","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Furtner","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Pichler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Neurooncology, Neuromed Campus, Kepler University Hospital, Johannes Kepler University of Linz, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruna","sequence":"additional","affiliation":[{"name":"Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-Institut Catal\u00e0 D\u2019Oncologia L\u2019Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Ducray","sequence":"additional","affiliation":[{"name":"Unit of Neuro-Oncology, Hospices Civils de Lyon, Lyon, France"},{"name":"Department of Cancer Cell Plasticity, Cancer Research Center of Lyon, Claude Bernard University, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap C","family":"Reijneveld","sequence":"additional","affiliation":[{"name":"Brain Tumor Center, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands"},{"name":"Stichting Epilepsie Instellingen Nederland, Heemstede, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mawrin","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Otto-von-Guericke-University, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Marosi","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Golfinopoulos","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Gorlia","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-634X","authenticated-orcid":false,"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"Neurology Clinic, Heidelberg University Medical Center, Clinical Cooperation Unit, Neurooncology, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"issue":"6","key":"2022050520130175600_CIT0001","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2022050520130175600_CIT0002","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"9","key":"2022050520130175600_CIT0003","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","article-title":"EANO guidelines for the diagnosis and treatment of meningiomas","volume":"17","author":"Goldbrunner","year":"2016","journal-title":"Lancet Oncol."},{"issue":"6","key":"2022050520130175600_CIT0004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol."},{"issue":"3","key":"2022050520130175600_CIT0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2022050520130175600_CIT0006","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-015-2927-0","article-title":"Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)","volume":"77","author":"Mazza","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"issue":"34","key":"2022050520130175600_CIT0007","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1200\/JCO.2015.61.6490","article-title":"Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005","volume":"33","author":"Ji","year":"2015","journal-title":"J Clin Oncol."},{"key":"2022050520130175600_CIT0008","doi-asserted-by":"crossref","DOI":"10.1111\/bph.14876","article-title":"Enriching cancer pharmacology with drugs of marine origin","author":"Jimenez","year":"2020","journal-title":"Br J Pharmacol."},{"issue":"2","key":"2022050520130175600_CIT0009","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell."},{"issue":"6","key":"2022050520130175600_CIT0010","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","article-title":"Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells","volume":"70","author":"Germano","year":"2010","journal-title":"Cancer Res."},{"key":"2022050520130175600_CIT0011","doi-asserted-by":"crossref","first-page":"56282","DOI":"10.1155\/SRCM\/2006\/56282","article-title":"Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients","volume":"2006","author":"Huygh","year":"2006","journal-title":"Sarcoma."},{"issue":"20","key":"2022050520130175600_CIT0012","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.27460","article-title":"Trabectedin has promising antineoplastic activity in high-grade meningioma","volume":"118","author":"Preusser","year":"2012","journal-title":"Cancer."},{"issue":"4","key":"2022050520130175600_CIT0013","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"issue":"2","key":"2022050520130175600_CIT0014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2022050520130175600_CIT0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2307\/2529759","article-title":"On the use of Pocock and Simon\u2019s method for balancing treatment numbers over prognostic factors in the controlled clinical trial","volume":"32","author":"Freedman","year":"1976","journal-title":"Biometrics."},{"issue":"5","key":"2022050520130175600_CIT0016","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7697","key":"2022050520130175600_CIT0017","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature."},{"issue":"11","key":"2022050520130175600_CIT0018","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022050520130175600_CIT0019","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2001.19.1.265","article-title":"Clinical trial designs for cytostatic agents: are new approaches needed?","volume":"19","author":"Korn","year":"2001","journal-title":"J Clin Oncol."},{"issue":"28","key":"2022050520130175600_CIT0020","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol."},{"key":"2022050520130175600_CIT0021","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 Health-Related Quality of Life Questionnaire based on 15,386 persons across 13 European countries, Canada and the United States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer."},{"issue":"2","key":"2022050520130175600_CIT0022","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2012","journal-title":"J Neurooncol."},{"issue":"1","key":"2022050520130175600_CIT0023","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol."},{"issue":"1","key":"2022050520130175600_CIT0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J Neurooncol."},{"issue":"2","key":"2022050520130175600_CIT0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14712598.2019.1559292","article-title":"Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs","volume":"19","author":"Dasanu","year":"2019","journal-title":"Expert Opin Biol Ther."},{"key":"2022050520130175600_CIT0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/sni.sni_264_17","article-title":"Role of bevacizumab for treatment-refractory meningiomas: a systematic analysis and literature review","volume":"9","author":"Franke","year":"2018","journal-title":"Surg Neurol Int."},{"issue":"2","key":"2022050520130175600_CIT0027","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","article-title":"A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma","volume":"129","author":"Shih","year":"2016","journal-title":"J Neurooncol."},{"issue":"3","key":"2022050520130175600_CIT0028","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/neuonc\/nov183","article-title":"Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma","volume":"18","author":"Furtner","year":"2016","journal-title":"Neuro Oncol."},{"issue":"1","key":"2022050520130175600_CIT0029","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J Neurooncol."},{"issue":"1","key":"2022050520130175600_CIT0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"Nayak","year":"2012","journal-title":"J Neurooncol."},{"issue":"20","key":"2022050520130175600_CIT0031","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med."},{"issue":"5","key":"2022050520130175600_CIT0032","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ane.13395","article-title":"Functional outcome and quality of life after meningioma surgery: a systematic review","volume":"143","author":"Corniola","year":"2021","journal-title":"Acta Neurol Scand."},{"issue":"25","key":"2022050520130175600_CIT0033","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022050520130175600_CIT0034","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11060-018-2912-7","article-title":"TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas","volume":"139","author":"Biczok","year":"2018","journal-title":"J Neurooncol."},{"issue":"2","key":"2022050520130175600_CIT0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","article-title":"Advances in meningioma genetics: novel therapeutic opportunities","volume":"14","author":"Preusser","year":"2018","journal-title":"Nat Rev Neurol."},{"issue":"12","key":"2022050520130175600_CIT0036","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","article-title":"TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma","volume":"20","author":"Spiegl-Kreinecker","year":"2018","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab243\/41145364\/noab243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/5\/755\/43548721\/noab243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/5\/755\/43548721\/noab243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:42:18Z","timestamp":1651768938000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/5\/755\/6406919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10,21]]},"published-print":{"date-parts":[[2022,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab243","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,10,21]]}}}